FCS Diagnosis and Management Explained: Clinical Forum Insights

After years in which low-density lipoprotein dominated dyslipidemia guidelines and clinical attention, new apolipoprotein C-III-targeted therapies are prompting clinicians to look harder at severe hypertriglyceridemia and the rare genetic disorder at its extreme, familial chylomicronemia syndrome (FCS).

Nihar Desai, MD, MPH, of Yale School of Medicine, moderated a clinical forum in New York titled "Familial Chylomicronemia Syndrome: Practical Approaches to Diagnosis and Management," walking participants through how to recognize FCS, where conventional triglyceride-lowering therapy falls short, and how apolipoprotein C-III inhibition is reshaping care.

What Is Familial Chylomicronemia Syndrome and How Common Is It?

Desai framed FCS as the tip of a much larger iceberg. An estimated 25% to 30% of the population has triglycerides above 150 mg/dL, roughly 1% has severe hypertriglyceridemia above 500 mg/dL, and only a fraction of a percent reaches levels above 1000 mg/dL, the range where persistent chylomicronemia and FCS are found. FCS itself, caused by biallelic loss-of-function variants in the lipoprotein lipase gene that leave chylomicrons and very low-density lipoprotein unable to clear from circulation, affects an estimated 1 in 1 million people, compared with an estimated 1 in 250 to 1 in 600 for multifactorial chylomicronemia syndrome, a more common, polygenic, and typically adult-onset condition.

Diagnostic Clues, Scoring Tools, and Pancreatitis Risk in FCS

Desai outlined the clinical features that separate FCS from garden-variety hypertriglyceridemia: triglycerides consistently above 880 mg/dL, a normal or lean body mass index rather than obesity, minimal or no response to statins, fibrates, or omega-3 fatty acids, and a history of recurrent acute pancreatitis. He reviewed diagnostic scoring systems used in North America and Europe that weigh age of onset, body mass index, pancreatitis history, and absence of secondary causes such as diabetes or alcohol use, noting that genetic testing is now widely available and should be pursued when the clinical picture is suggestive.

Diagnostic delay remains common; patients see an average of 5 physicians before an FCS diagnosis is made, nearly half are initially misdiagnosed, and about three-quarters are identified within the first decade of life, leaving the remainder to be picked up later, often after a pancreatitis admission.¹

Pancreatitis risk was a recurring theme. Desai cited data showing a 17-fold increase in pancreatitis risk at triglycerides above 1000 mg/dL and a threefold increase at 500 to 600 mg/dL, with a lifetime pancreatitis risk of 60% to 90% in FCS and recurrent episodes in more than half of affected patients.

Participants discussed how repeated pancreatitis admissions can progress to pancreatogenic diabetes, and how the disease's early onset and dietary restrictions, a diet limited to roughly 10% of calories from fat, supplemented with medium-chain triglycerides and fat-soluble vitamins, and near-total abstinence from alcohol, extend well beyond clinical management into a patient's daily life.

Desai noted that one-third of patients report FCS significantly limits travel and socializing, and two-thirds report effects on self-worth, sleep, and emotional well-being.¹

Targeting Apolipoprotein C-III: Olezarsen and Plozasiran Trial Data

The forum's central clinical update centered on apolipoprotein C-III inhibition. Desai explained that apolipoprotein C-III normally inhibits lipoprotein lipase, and that silencing its hepatic production can re-engage lipoprotein lipase-independent clearance pathways even in patients with little or no functional lipoprotein lipase. Two therapies now target this pathway: olezarsen, an antisense oligonucleotide dosed monthly and FDA-approved in December 2024, and plozasiran, a small interfering RNA dosed every 3 months.

In the Balance trial, the 80-mg dose of olezarsen produced a statistically significant reduction in triglycerides in genetically confirmed FCS, while the 50-mg dose did not reach significance, with numerically lower rates of serious adverse events and pancreatitis in the treatment arms.² In the Palisade trial, which enrolled patients with either genetically confirmed FCS or a clinical diagnosis of persistent chylomicronemia, plozasiran produced roughly an 80% reduction in triglycerides and a statistically significant 83% relative reduction in pancreatitis risk.³

Participants weighed the practical and scientific implications of these results. Several noted that less frequent dosing, monthly or quarterly injections rather than the more frequent regimens required by some other lipid-lowering biologics, matters meaningfully to patients managing a lifelong condition. Others pushed for outcomes data beyond triglyceride and pancreatitis endpoints, including cardiovascular event reduction, as these agents are studied in the broader severe hypertriglyceridemia population beyond ultra-rare FCS.

The forum closed on that expectation: as apolipoprotein C-III inhibition moves from an orphan indication toward a larger patient population, participants agreed the field will need to meet the same evidentiary bar already set for other lipid therapies.

References

1. Davidson M, Stevenson M, Hsieh A, Ahmad Z, Roeters van Lennep J, Crowson C, Witztum JL. The burden of familial chylomicronemia syndrome: results from the global IN-FOCUS study. J Clin Lipidol. 2018;12(4):898-907.

2. Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024;390(19):1781-1792.

3. Watts GF, Rosenson RS, Hegele RA, et al. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. N Engl J Med. 2025;392(2):127-137.